Glaukos Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Related Search

Listing Results Glaukos Contact Number

Contact Us Glaukos

5 hours ago Glaukos.com Get All

949-367-9600Phone: +1-949-367-9600 Fax: +1-949-367-9984 229 Avenida Fabricante, San Clemente, CA 92672 United States

Website: https://www.glaukos.com/contact-us/

Category: Customer service phone numberShow more

Contact Us Glaukos

1 hours ago Glaukos.com Get All

949-367-9600Phone: +1-949-367-9600 Fax: +1-949-367-9984 229 Avenida Fabricante, San Clemente, CA 92672 United States

Website: https://www.glaukos.com/en-uk/contact-us/

Category: Box customer serviceShow more

International Contacts Glaukos

8 hours ago Glaukos.com Get All

12.29.235

1. Glaukos Canada 95 Mural Street, 6th Floor, Richmond Hill, ON L4B3G2 Phone: 905-695-3555 Fax: 905-305-6649 Customer Service Phone: 844-GLAUKOS (452-8567) Customer Service Fax: 844-452-8329 General Manager: Kevin Shearer: [email protected]

Website: https://www.glaukos.com/international/

Category: Seamless customer serviceShow more

Glaukos Corporation Company Profile San Clemente, CA

3 hours ago Dnb.com Get All

(949) 367-9600Glaukos Corporation is located in San Clemente, CA, United States and is part of the {{industry}} Industry. Glaukos Corporation has 387 total employees across all of its locations and generates $224.96 million in sales (USD). There are 15 companies in the Glaukos

Employees: 387
Phone: (949) 367-9600
Location: 229 Avenida Fabricante, San Clemente, 92672-7531

Website: https://www.dnb.com/business-directory/company-profiles.glaukos_corporation.8e8ca49a52f88d7ec09cdbf3312af0f1.html

Category: Jcs customer serviceShow more

Glaukos Crunchbase Company Profile & Funding

7 hours ago Crunchbase.com Get All

Contact Email contact@glaukos.com Phone Number 19493679984 Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness.

Founded: 1998
Founders: Richard A. Hill, Olav Bergheim, Mory Gharib

Website: https://www.crunchbase.com/organization/glaukos

Category: Ahin customer serviceShow more

Glaukos Corporation Glaukos and Avedro Announce

4 hours ago Investors.glaukos.com Get All

949-481-0510Glaukos Investor Contact: Chris Lewis, Director, Investor Relations, Corporate Development & Strategy 949-481-0510 [email protected]glaukos.com. Glaukos Media Contact: Cassandra Dump 619-971-1887 [email protected] Avedro Investor Contact: Brian Johnston or Lynn Lewis 631-807-1986 [email protected] Source: Glaukos

Website: http://investors.glaukos.com/investors/press-releases/press-release-details/2019/Glaukos-and-Avedro-Announce-Definitive-Acquisition-Agreement/default.aspx

Category: Contact NumberShow more

Glaukos: Customer Service Representative WayUp

Just Now Wayup.com Get All

Glaukos is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world's leading causes of blindness.

Website: https://www.wayup.com/i-j-Glaukos-321567694221155/

Category: Customer ServiceShow more

Glaukos

Just Now Glaukos.com Get All

Glaukos started a revolution in glaucoma surgery and treatment with the development of the first Micro-Invasive Glaucoma Surgery device. To date, trabecular micro-bypass technologies such as iStent ®, iStent inject ®, and iStent inject ® W have been implanted in over 600,000 eyes around the world, with more patients benefitting from these

Website: https://www.glaukos.com/en-uk/

Category: Contact NumberShow more

Glaukos Corporation Email Format glaukos.com Emails

2 hours ago Rocketreach.co Get All

Glaukos Corporation uses 1 email formats, with first_initial last (ex. [email protected]glaukos.com) being used 100.0% of the time. Get Verified Emails for Glaukos Corporation Employees. Glaukos Corporation's Email Format. Percentage.

Website: https://rocketreach.co/glaukos-corporation-email-format_b5ce990df42e0951

Category: Contact NumberShow more

Glaukos Home Facebook

7 hours ago Facebook.com Get All

Glaukos. July 28 at 8:00 AM ·. Dr. Matthew Robinson of Ochsner Eye cites routine appointments as crucial to tracking patient disease state, especially for glaucoma. As symptoms aren’t always detectable unless by an eye care professional, they can lead to more severe outcomes if …

Website: https://www.facebook.com/GlaukosCorp/

Category: Home PhoneShow more

Contact details GlaUKos UK Ltd NHS

6 hours ago Nhs.uk Get All

GlaUKos UK Ltd. Address: White Hart House, High Street, Limpsfield, Oxted, Surrey, RH8 0DT. Contact hospitals we provide services at. Contact specific departments and services.

Location: White Hart House, High Street, Limpsfield

Website: https://www.nhs.uk/Services/Trusts/ContactDetails/DefaultView.aspx?id=141693

Category: Contact SupportShow more

Advancing the Treatment of Ophthalmic Diseases Glaukos

6 hours ago Glaukos.com Get All

Corporate Overview. Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Our company was the first company to bring to market Micro-Invasive Glaucoma Surgery (MIGS), the micro-invasive procedure which

Website: https://www.glaukos.com/au

Category: Contact NumberShow more

GLAUKOS SINGAPORE PTE. LTD. Company Profile Singapore

9 hours ago Dnb.com Get All

77 Robinson Road. #13-00 Robinson 77. Singapore , 068896. Singapore. See other locations. Phone. +65-65006476. Company Description. GLAUKOS SINGAPORE PTE. LTD. is located in Singapore, Singapore and is part of the Medical Equipment and Supplies Manufacturing Industry.

Website: https://www.dnb.com/business-directory/company-profiles.glaukos_singapore_pte_ltd.ee8724156bfa83e72f42c9cd98e74047.html

Category: Contact NumberShow more

Patents Glaukos

2 hours ago Glaukos.com Get All

Patent Notice The following list serves as notice under 35 U.S.C. § 287(a) that the listed Glaukos® products are covered by the following U.S. patents. Each product may also be covered by one or more patents in other jurisdictions, and additional patent applications may be pending. The absence of a product name from this list … Continued

Website: https://www.glaukos.com/patents/

Category: Contact NumberShow more

Glaukos Corporation (GKOS) Company Profile & Facts Yahoo

5 hours ago Finance.yahoo.com Get All

See the company profile for Glaukos Corporation (GKOS) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and

Website: https://finance.yahoo.com/quote/GKOS/profile/

Category: Contact NumberShow more

Glaukos Company Profile Office Locations, Competitors

4 hours ago Craft.co Get All

Glaukos has 600 employees across 23 locations and $224.96 M in annual revenue in FY 2020. See insights on Glaukos including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Website: https://craft.co/glaukos

Category: Contact NumberShow more

Contact details GlaUKos UK Cavendish Square NHS

Just Now Nhs.uk Get All

GlaUKos UK - Cavendish Square. Address: 33 Cavendish Square, Marylebone, London, Greater London, W1G 0PW

Website: https://www.nhs.uk/Services/clinics/MapsAndDirections/DefaultView.aspx?id=147564

Category: Contact SupportShow more

Glaukos Corporation Glaukos Announces Licensing

9 hours ago Investors.glaukos.com Get All

(619) 971-1887Media Contact: Cassandra Dump (619) 971-1887 [email protected] Investor Contact: Chris Lewis Sr. Director, Investor Relations & Corporate Strategy & Development (949) 481-0510 [email protected]glaukos.com Source: Glaukos Corporation

Website: http://investors.glaukos.com/investors/press-releases/press-release-details/2021/Glaukos-Announces-Licensing-Agreement-with-Attillaps-Holdings-Inc/default.aspx

Category: Contact NumberShow more

Glaukos Corp. to Host Earnings Call Yahoo

7 hours ago Finance.yahoo.com Get All

NEW YORK, NY / ACCESSWIRE / May 5, 2021 / Glaukos Corp. (NYSE:GKOS) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 5, 2021 at 4:30 PM Eastern

Website: https://finance.yahoo.com/news/glaukos-corp-host-earnings-call-184500003.html

Category: Contact NumberShow more

GKOS Stock Glaukos Corp SEC Filings

Just Now Sec.report Get All

020-11-20Date of Edgar Filing Update. 2020-11-20. SIC. 3841 [SURGICAL & MEDICAL INSTRUMENTS & APPARATUS] Business Address. 229 AVENIDA FABRICANTE. SAN CLEMENTE CA 92672. Business Phone. 949-367-9600.

Website: https://sec.report/Ticker/GKOS

Category: Contact NumberShow more

Glaukos Corp (GKOS) 10K Annual Reports & 10Q SEC Filings

6 hours ago Last10k.com Get All

(949) 481-0510Contact: Chris Lewis. Director, Investor Relations, Corporate Strategy & Development (949) 481-0510. [email protected]glaukos.com. Glaukos Corporation Announces Fourth Quarter and Full Year 2020 Financial Results. San Clemente, CA – February 25, 2021 –

Website: https://last10k.com/sec-filings/gkos

Category: Contact NumberShow more

Company Glaukos News, Employees and Funding Information

2 hours ago Topionetworks.com Get All

Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. Glaukos has pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and …

Website: https://www.topionetworks.com/companies/glaukos-5306faf10888ed0453000614

Category: Contact NumberShow more

GET THERE IN TIME Excel Eye Center

6 hours ago Exceleyecenter.com Get All

VISIT GLAUKOS.COM OR CONTACT YOUR GLAUKOS REPRESENTATIVE • Only FDA-approved cross-linking procedure • Wide reimbursement coverage • Backed by Glaukos comprehensive support REFERENCES: 1. Photrexa [package insert]. Waltham, MA: Glaukos

Website: https://www.exceleyecenter.com/wp-content/uploads/2020/10/iLink-Brochure.pdf

Category: Contact NumberShow more

Glaukos B4Plastics

4 hours ago B4plastics.com Get All

Glaukos materials are advancing B4plastics’ proprietary FortePlastics technology platform: finetuning the balance between strength and controlled degradability to build the most advanced and degradable textiles and fishing gear products in the world. Explore our FortePlastics technology platform and contact us to learn more.

Website: https://www.b4plastics.com/projects/glaukos/

Category: Contact NumberShow more

MAUDE Adverse Event Report: GLAUKOS CORPORATION ISTENT

Just Now Accessdata.fda.gov Get All

Model Number G2-W: Device Problem Adverse Event Without Identified Device or Use Problem (2993) Patient Problem Macular Edema (1822) Event Type Injury Manufacturer Narrative Additional information: the device was not available; therefore, product testing on the actual device could not be performed.

Website: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/detail.cfm?mdrfoi__id=12378163&pc=OGO

Category: Contact NumberShow more

Glaukos Corporation Investors Resources & Alerts FAQs

7 hours ago Investors.glaukos.com Get All

The Glaukos corporate headquarters is located at 26051 Merit Circle, Suite 103, Laguna Hills, CA 92653.

Website: http://investors.glaukos.com/investors/resources-and-alerts/faqs/default.aspx

Category: Contact NumberShow more

Glaukos Announces MarketLeading Clinical Milestone of 200

3 hours ago Aijourn.com Get All

A significant number of clinical studies for both current and future products are ongoing, with additional studies commencing in the near future. About Glaukos Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.

Website: https://aijourn.com/press_release/glaukos-announces-market-leading-clinical-milestone-of-200-peer-reviewed-publications-on-istent-technologies/

Category: Contact NumberShow more

Here’s How Your Trade Glaukos Corporation (GKOS

3 hours ago Newsheater.com Get All

Glaukos Corporation (NYSE:GKOS) went up by 3.08% from its latest closing price compared to the recent 1-year high of $99.00. The company’s stock price has collected 14.38% of gains in the last five trading sessions. Press Release reported 16 hours ago that Glaukos Announces Participation in the We

Website: https://newsheater.com/2021/08/27/heres-how-your-trade-glaukos-corporation-gkos-aggressively-right-now/

Category: Contact NumberShow more

Glaukos Corporation Investors Investor Overview

9 hours ago Investors.glaukos.com Get All

949-481-0510September 3, 2021 Glaukos Announces Submission of Supplemental Pre-Market Approval Application for iStent infinite Contact Investor Relations. Glaukos Corporation 229 Avenida Fabricante San Clemente, CA 92672 Telephone: 949-481-0510 Fax: 949-367-9984 Email: [email protected]glaukos.com.

Website: http://investors.glaukos.com/investors/investor-overview/default.aspx

Category: Contact NumberShow more

GLAUKOS SINGAPORE PTE. LTD. (201633642H) Singapore …

1 hours ago Sgpbusiness.com Get All

GLAUKOS SINGAPORE PTE. LTD. Registration No. / Unique Entity Number: 201633642H GLAUKOS SINGAPORE PTE. LTD. (the "Company") is a Private Company Limited by Shares, incorporated on 9 December 2016 (Friday) in Singapore. The address of the Company's registered office is at the ROBINSON 77 building.

Website: https://www.sgpbusiness.com/company/Glaukos-Singapore-Pte-Ltd

Category: Contact NumberShow more

Glaukos Corporation Glaukos Corporation Announces Third

Just Now Investors.glaukos.com Get All

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2020. Key highlights include: Net sales of $64.8 million in Q3 2020, compared …

Website: http://investors.glaukos.com/investors/press-releases/press-release-details/2020/Glaukos-Corporation-Announces-Third-Quarter-2020-Financial-Results/default.aspx

Category: Contact NumberShow more

Glaukos Announces Licensing Agreement with Attillaps

3 hours ago Finance.yahoo.com Get All

(619) 971-1887Media Contact: Cassandra Dump (619) 971-1887 [email protected] Investor Contact: Chris Lewis Sr. Director, Investor Relations & Corporate Strategy & Development (949) 481-0510

Website: https://finance.yahoo.com/news/glaukos-announces-licensing-agreement-attillaps-110000902.html

Category: Contact NumberShow more

Glaukos Corporation Glaukos Corporation Announces

8 hours ago Investors.glaukos.com Get All

Glaukos Corporation (NYSE: GKOS) (the “Company” or “Glaukos”), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today the pricing of its private offering of $250 million aggregate principal amount of 2.75% Convertible Senior Notes …

Website: http://investors.glaukos.com/investors/press-releases/press-release-details/2020/Glaukos-Corporation-Announces-Pricing-of-Private-Offering-of-250-Million-of-275-Convertible-Senior-Notes/default.aspx

Category: Contact NumberShow more

Glaukos Announces Licensing Agreement with Attillaps

Just Now Ca.movies.yahoo.com Get All

(619) 971-1887Media Contact: Cassandra Dump (619) 971-1887 [email protected] Investor Contact: Chris Lewis Sr. Director, Investor Relations & Corporate Strategy & Development (949) 481-0510 [email protected]glaukos.com

Website: https://ca.movies.yahoo.com/glaukos-announces-licensing-agreement-attillaps-110000902.html

Category: Contact NumberShow more

Glaukos : Announces Submission of Supplemental PreMarket

5 hours ago Marketscreener.com Get All

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has submitted a supplemental pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the iStent …

Website: https://www.marketscreener.com/quote/stock/GLAUKOS-CORPORATION-22619559/news/Glaukos-Announces-Submission-of-Supplemental-Pre-Market-Approval-Application-for-iStent-infinite-t-36317800/

Category: Contact NumberShow more

Glaukos (GKOS) Announces PMA Submission, Boosts iStent

3 hours ago Finance.yahoo.com Get All

Glaukos (GKOS) submits PMA application to the FDA, which can enhance the company's deep portfolio of novel glaucoma surgical devices and sustained pharmaceuticals.

Website: https://finance.yahoo.com/news/glaukos-gkos-announces-pma-submission-132401921.html

Category: Contact NumberShow more

Glaukos Announces Settlement of Patent Litigation with

2 hours ago Finance.yahoo.com Get All

(619) 971-1887Media Contact: Cassandra Dump (619) 971-1887 [email protected] Investor Contact: Chris Lewis Sr. Director, Investor Relations & Corporate Strategy & Development (949) 481-0510

Website: https://finance.yahoo.com/news/glaukos-announces-settlement-patent-litigation-110000401.html

Category: Contact NumberShow more

Glaukos Corporation Investors Corporate Governance

8 hours ago Investors.glaukos.com Get All

Mr. Burns has served as our President, Chief Executive Officer and as a member of our Board of Directors since March 2002. Mr. Burns was also a founder and member of the board of directors of DOSE Medical Corporation (acquired by Glaukos), serving as its chairman of the board from October 2009 until June 2019 and its chief executive officer and president from March 2010 …

Website: http://investors.glaukos.com/Investors/Corporate-Governance/Management-Team/default.aspx

Category: Contact NumberShow more

Glaukos Corporation (GKOS): The stock medium term

9 hours ago Baxterreport.com Get All

Glaukos Corporation (GKOS) saw an uptrend of 2.56% in the recent trading with $52.56 being its most recent. The current price level -46.91% lower than the highest price of $99.00 marked by the stock while trading over the past 52-weeks, whereas it is 16.64% higher than the lowest price of $45.06 the company dropped to over past 52-weeks.

Website: https://baxterreport.com/2021/09/24/glaukos-corporation-gkos-the-stock-medium-term-indicators-say-sell-today/

Category: Contact NumberShow more

GKOS Stock Forecast, Price & News (Glaukos) MarketBeat

4 hours ago Marketbeat.com Get All

(949) 367-9600How can I contact Glaukos? Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672 . The medical instruments supplier can be reached via phone at (949) 367-9600 or via email at [email protected] .

Website: https://www.marketbeat.com/stocks/NYSE/GKOS/

Category: Contact NumberShow more

Glaukos : Announces Licensing Agreement with Attillaps

2 hours ago Marketscreener.com Get All

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Attillaps Holdings, Inc. under which Attillaps has granted Glaukos a global exclusive …

Website: https://www.marketscreener.com/quote/stock/GLAUKOS-CORPORATION-22619559/news/Glaukos-Announces-Licensing-Agreement-with-Attillaps-Holdings-Inc-36465463/

Category: Contact NumberShow more

1. GENERAL INFORMATION GTS1OOR, GTSIOOL)

8 hours ago Accessdata.fda.gov Get All

Device Trade Name: Glaukos iStentV Trabecular Micro-Bypass Stent (Models: GTS-1OOR, GTS-IOOL) and inserter (GTS-100i) Device Procode: OGO Applicant's Name and Address: Glaukos Corporation 26051 Merit Circle, Suite 103 Laguna Hills, CA 92653 Date(s) of Panel Recommendation: July 30, 2010 PMA Number: P080030

Website: https://www.accessdata.fda.gov/cdrh_docs/pdf8/P080030b.pdf

Category: Contact NumberShow more

Saikat Dutta Country Manager India Glaukos

7 hours ago In.linkedin.com Get All

A continuously evolving professional with overall 20 years of experience in Pharma & Medical devices across diverse roles (Medical, Marketing, Business development,Leadership, Matrix team management, Quality & Compliance) gained through working across 5 organizations, 10 therapeutic segments and 2 countries.

Title: Country Head-India || Glaukos
Location: Mumbai Suburban district, Maharashtra, India
1. 500+ connections

Website: https://in.linkedin.com/in/saikat-dutta-45a702a

Category: Contact NumberShow more

Glaukos Co. (NYSE:GKOS) Short Interest Down 25.6% in

4 hours ago Marketbeat.com Get All

Glaukos Co. (NYSE:GKOS) was the recipient of a significant drop in short interest in the month of August. As of August 13th, there was short interest totalling 2,030,000 shares, a drop of 25.6% from the July 29th total of 2,730,000 shares. Currently, 4.6% of the company's stock are sold short. Based on an average trading volume of 559,400 shares, the short …

Website: https://www.marketbeat.com/instant-alerts/nyse-gkos-options-data-report-2021-08-2-3/

Category: Contact NumberShow more

Glaukos : Agrees to Stop Patent Litigation Against Ivantis

3 hours ago Marketscreener.com Get All

Glaukos : Agrees to Stop Patent Litigation Against Ivantis in Exchange for $60 Million Payment, Royalty Share

Website: https://www.marketscreener.com/quote/stock/GLAUKOS-CORPORATION-22619559/news/Glaukos-Agrees-to-Stop-Patent-Litigation-Against-Ivantis-in-Exchange-for-60-Million-Payment-Roya-36430827/

Category: Contact NumberShow more

Glaukos Provides COVID19 Pandemic Update Eyewire+

7 hours ago Eyewire.news Get All

Glaukos provided an update on the actions it is taking in response to the COVID-19 pandemic. In order to prioritize the health and safety of employees, healthcare professionals, patients and its communities, while continuing to support its customers, Glaukos implemented a number of measures:

Website: https://eyewire.news/news/glaukos-provides-covid-19-pandemic-update

Category: Contact NumberShow more

Analysts Expect Glaukos Co. (NYSE:GKOS) Will Post Earnings

9 hours ago Marketbeat.com Get All

Glaukos had a negative return on equity of 3.13% and a negative net margin of 21.24%. The firm had revenue of $78.09 million during the quarter, compared to the consensus estimate of $71.00 million. GKOS has been the subject of a number of research reports.

Website: https://www.marketbeat.com/instant-alerts/nyse-gkos-consensus-analyst-rating-2021-09-2-3/

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What kind of medical company is Glaukos Corporation?

Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.

Is there a good way to buy Glaukos stock?

Wall Street analysts have given Glaukos a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Glaukos wasn't one of them. MarketBeat thinks these five companies may be even better buys.

What are the analysts'ratings on Glaukos?

The consensus among Wall Street analysts is that investors should "hold" Glaukos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GKOS, but not buy additional shares or sell existing shares. View analyst ratings for Glaukos or view top-rated stocks.

When is the Glaukos company earnings conference call?

Glaukos will be holding an earnings conference call on Thursday, August 5th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Glaukos' earnings last quarter? Glaukos Co. (NYSE:GKOS) released its earnings results on Wednesday, May, 5th.

Popular Brands

Godrej
Gbl
Geely
Gati
Gic
Gevo
Geron
Gaia
Gpa